BiotechTube
SocraTec R&D

SocraTec R&D

Ober-Mörlen, Germany· Est.
socratec-pharma.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

SocraTec R&D is a privately-held, revenue-generating contract research organization based in Ober-Mörlen, Germany, providing integrated drug development services. The company's core asset is its owned and operated Clinical Pharmacology Unit in Erfurt, a modular facility designed for adaptive early-phase (Phase I/II) and bioequivalence studies. With a strong scientific focus on pharmacokinetics, BA/BE, and specialized drug delivery (e.g., transdermal, inhalational, ophthalmological), SocraTec positions itself as a specialized partner for pharmaceutical sponsors, from biotechs to larger companies, navigating complex clinical and regulatory pathways.

OncologyOphthalmologyGynecologyNeurology (e.g., Parkinson's)Various (via BA/BE services)

Technology Platform

Integrated clinical service platform centered on a proprietary, modular Clinical Pharmacology Unit (CPU) for Phase I/II trials, with specialized scientific expertise in pharmacokinetics, bioequivalence, and complex drug delivery systems (transdermal, inhalational, ophthalmological).

Opportunities

Growth in the biosimilar and complex generic drug markets drives demand for sophisticated bioequivalence and pharmacokinetic studies.
Increasing industry outsourcing of early-phase clinical development to specialized, flexible CROs presents a continued opportunity for client acquisition.

Risk Factors

Revenue is contingent on a competitive project-based business model, subject to client budget cycles and industry R&D spending fluctuations.
Operational and regulatory risks are inherent in clinical trial conduct, where any significant quality issue or safety event could severely impact reputation and viability.

Competitive Landscape

Competes in a fragmented CRO market, ranging from global full-service giants (e.g., IQVIA, LabCorp) to numerous niche European players. Differentiation is based on deep scientific expertise in early-phase PK/BA/BE, ownership of a dedicated CPU, and specialization in complex drug delivery routes like transdermal and inhalation.

More companies in Digital Health & Biotech SaaS →More companies in Germany →